Biostatistics & Data Science
Discover how we use data science methods on clinical trials data to develop patient-led innovations and breakthrough treatments.
Search
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
FDA approves additional formulation of biosimilar
US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.
BI & Lilly Announce Outcome of FDA Advisory Meeting | Boehringer Ingelheim US
The EASE phase III program includes two Phase III clinical trials to investigate the efficacy, safety and tolerability of once-daily Empagliflozin.
First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies
First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies
Translational Medicine & Clinical Pharmacology
We connect the right patient with the right drug on the right dosing schedule using data science methods from pharmacometrics to systems pharmacology.
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial
Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial
New agreement with Quallent expands biosimilar access
Boehringer Ingelheim enters private label agreement for biosimilar
PI Update for Pradaxa® (dabigatran etexilate) | BI US
Read more about three important announcements regarding the US prescribing information of the oral anticoagulant (OAC) PRADAXA, for patients with NVAF.
COPD_Patient_brochure.pdf
The BI Cares Patient Assistance Program - Editable Form
The BI Cares Patient Assistance Program - Gilotrif® - Fillable Form
The BI Cares Patient Assistance Program - Ofev® - Fillable Form
The BI Cares Patient Assistance Program
The BI Cares Patient Assistance Program - Gilotrif®
The BI Cares Patient Assistance Program - Ofev®
Patient information
Patient-centric cardio-renal-metabolic disease research at Boehringer Ingelheim
Patient Assistance Program Application form - Spanish
Patient Assistance Program Gilotrif Application editable form - Spanish
Patient Assistance Program Gilotrif Application form - Spanish
Patient Assistance Program Ofev Application editable form - Spanish
Patient Assistance Program Ofev Application form - Spanish
Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD
Phase III study showed Ofev slows the loss of pulmonary function in people living with systemic sclerosis associated ILD